Literature DB >> 9450538

HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor.

K Date1, K Matsumoto, H Shimura, M Tanaka, T Nakamura.   

Abstract

We prepared a specific antagonist for hepatocyte growth factor (HGF) and designated it HGF/NK4. HGF/NK4 is composed of N-terminal 447 amino acids of the alpha-chain of HGF, thus contains the N-terminal hairpin domain and subsequent four kringle domains. HGF/NK4 competitively inhibited the specific binding of HGF to the receptor. Importantly, HGF/NK4 neither stimulated DNA synthesis of primary cultured rat hepatocytes (mitogenesis) nor induced cell scattering (motogenesis) and branching tubulogenesis (morphogenesis) of MDCK renal epithelial cells, however, HGF/NK4 almost completely inhibited the mitogenic, motogenic, and morphogenic activities of HGF. HGF/NK4 also suppressed tyrosine phosphorylation of the c-Met/HGF receptor induced by HGF. Apparently this is the first documentation of a specific antagonist which abrogates the mitogenic, motogenic, and morphogenic activities of HGF.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9450538     DOI: 10.1016/s0014-5793(97)01475-0

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  60 in total

1.  Identification of mannose receptor as receptor for hepatocyte growth factor β-chain: novel ligand-receptor pathway for enhancing macrophage phagocytosis.

Authors:  Hiroyuki Ohnishi; Kiyomasa Oka; Shinya Mizuno; Toshikazu Nakamura
Journal:  J Biol Chem       Date:  2012-02-21       Impact factor: 5.157

Review 2.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

3.  Alternative proteolytic processing of hepatocyte growth factor during wound repair.

Authors:  Nils Buchstein; Daniel Hoffmann; Hans Smola; Sabina Lang; Mats Paulsson; Catherin Niemann; Thomas Krieg; Sabine A Eming
Journal:  Am J Pathol       Date:  2009-04-23       Impact factor: 4.307

4.  Effects of adenoviral-mediated gene transduction of NK4 on proliferation, movement, and invasion of human colonic LS174T cancer cells in vitro.

Authors:  Jian-Zheng Jie; Jian-Wei Wang; Jian-Guo Qu; Wei Wang; Tao Hung
Journal:  World J Gastroenterol       Date:  2006-07-07       Impact factor: 5.742

Review 5.  The vasculature in rheumatoid arthritis: cause or consequence?

Authors:  Ewa M Paleolog
Journal:  Int J Exp Pathol       Date:  2009-06       Impact factor: 1.925

6.  Mast cell and neutrophil peptidases attack an inactivation segment in hepatocyte growth factor to generate NK4-like antagonists.

Authors:  Wilfred W Raymond; Anthony C Cruz; George H Caughey
Journal:  J Biol Chem       Date:  2005-11-22       Impact factor: 5.157

7.  Structural basis for agonism and antagonism of hepatocyte growth factor.

Authors:  W David Tolbert; Jennifer Daugherty-Holtrop; Ermanno Gherardi; George Vande Woude; H Eric Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

8.  NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells.

Authors:  Takeshi Kubota; Hiroaki Taiyoh; Atsushi Matsumura; Yasutoshi Murayama; Daisuke Ichikawa; Kazuma Okamoto; Hitoshi Fujiwara; Hisashi Ikoma; Masayoshi Nakanishi; Shojiro Kikuchi; Chouhei Sakakura; Toshiya Ochiai; Yukihito Kokuba; Hiroki Taniguchi; Teruhisa Sonoyama; Kunio Matsumoto; Toshikazu Nakamura; Eigo Otsuji
Journal:  Clin Exp Metastasis       Date:  2009-02-21       Impact factor: 5.150

9.  Analysis of HGF, MACC1, C-met and apoptosis-related genes in cervical carcinoma mice.

Authors:  Xiao-Ping Chen; Xin-Ping Ren; Jian-Yun Lan; You-Guo Chen; Zong-Ji Shen
Journal:  Mol Biol Rep       Date:  2014-01-28       Impact factor: 2.316

10.  Suppression of the progress of disseminated pancreatic cancer cells by NK4 plasmid DNA released from cationized gelatin microspheres.

Authors:  Toshihiro Kushibiki; Kunio Matsumoto; Toshikazu Nakamura; Yasuhiko Tabata
Journal:  Pharm Res       Date:  2004-07       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.